Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
IDO1 encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. Additionally we are shipping Indoleamine 2,3-Dioxygenase 1 Kits (14) and Indoleamine 2,3-Dioxygenase 1 Proteins (14) and many more products for this protein.
Showing 10 out of 176 products:
Human Polyclonal IDO1 Primary Antibody for IF (cc), IF (p) - ABIN1714836
Fu, Zhang, Song, Sheng, Li, Li, Song, Wang, Chu, Wei: Effect of bone marrow-derived CD11b(+)F4/80 (+) immature dendritic cells on the balance between pro-inflammatory and anti-inflammatory cytokines in DBA/1 mice with collagen-induced arthritis. in Inflammation research : official journal of the European Histamine Research Society ... [et al.] 2014
Show all 2 references for ABIN1714836
Human Polyclonal IDO1 Primary Antibody for EIA, FACS - ABIN1107630
Grohmann, Fallarino, Puccetti: Tolerance, DCs and tryptophan: much ado about IDO. in Trends in immunology 2003
Show all 2 references for ABIN1107630
Human Polyclonal IDO1 Primary Antibody for IHC (p), WB - ABIN389194
Maghzal, Thomas, Hunt, Stocker: Cytochrome b5, not superoxide anion radical, is a major reductant of indoleamine 2,3-dioxygenase in human cells. in The Journal of biological chemistry 2008
Show all 2 references for ABIN389194
Human Polyclonal IDO1 Primary Antibody for EIA, IHC (p) - ABIN357869
Scheler, Wenzel, Tüting, Takikawa, Bieber, von Bubnoff: Indoleamine 2,3-dioxygenase (IDO): the antagonist of type I interferon-driven skin inflammation? in The American journal of pathology 2007
Show all 2 references for ABIN357869
Human Polyclonal IDO1 Primary Antibody for IF, IHC - ABIN185488
Munn, Sharma, Baban, Harding, Zhang, Ron, Mellor: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. in Immunity 2005
Mouse (Murine) Polyclonal IDO1 Primary Antibody for IHC (fro), IHC (p) - ABIN1107631
Hill, Pereira, Chauveau, Zagani, Remy, Tesson, Mazal, Ubillos, Brion, Asghar, Ashgar, Mashreghi, Kotsch, Moffett, Doebis, Seifert, Boczkowski, Osinaga, Anegon: Heme oxygenase-1 inhibits rat and human breast cancer cell proliferation: mutual cross inhibition with indoleamine 2,3-dioxygenase. in FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005
Mouse (Murine) Monoclonal IDO1 Primary Antibody for FACS, IP - ABIN1043734
Mellor, Munn: IDO expression by dendritic cells: tolerance and tryptophan catabolism. in Nature reviews. Immunology 2004
Differential expression of CD25 (show IL2RA Antibodies) and IDO mRNA with high and low virulence bovine viral diarrhea virus might reflect temporal differences in transcription during the immune response elicited by these viral strains.
IDO may be involved in downregulating immune responses to M. avium subsp. paratuberculosis and other virulent mycobacteria, which may be an example of the pathogen harnessing host immunoregulatory pathways to aid survival.
INDO participates in IFN-gama-induced death of bovine luteal cells, through a mechanism that involves degradation of tryptophan, thereby reducing tryptophan concentrations to a point insufficient to meet luteal cells needs
SIV-infected macaques exhibiting progression to AIDS displayed greater expression of TGF-beta (show TGFB1 Antibodies) and indoleamine 2,3 dioxygenase in CD8 (show CD8A Antibodies)+ T cells from mesentric lymph nodes.
High IDO1 expression is associated with cervical cancer.
PSG stimulated IDO activity under the conditions of induction of the monocytes by interferon-gamma (show IFNG Antibodies).
These results indicate that the level of IDO expression may be associated with pregnancy-related complications, such as URSA, by affecting trophoblast cell proliferation and migration via the STAT3 (show STAT3 Antibodies) signaling pathway.
IDO is a potential prognostic biomarker for overall survival of patients with gastric adenocarcinoma after gastrectomy.
IDO expressed by placenta cells can down-regulate NKp46 (show NCR1 Antibodies) and NKG2D (show KLRK1 Antibodies) expression and reduce cytotoxicity in NK cells, suggesting an important role for IDO in the maintenance of normal pregnancy
Results suggest that IDO expression is implicated in immunosuppression and tumor progression in glioma cells; combining IDO inhibition with standard TMZ treatment could be an encouraging therapeutic strategy for patients with malignant glioma
Results suggest Withaferin A (WA) as a valuable small ligand molecule with strong binding affinity toward indoleamine 2,3-dioxygenase (IDO).
Our results imply the probability of involvement of IDO in development of tolerance process, and we presume that high IDO activity is associated with nonresponsiveness to food allergens despite allergen sensitization.
IDO, through GCN2 (show EIF2AK4 Antibodies) kinase activation, downregulates the levels of TCRcomplex tchain and cMyc (show MYC Antibodies), resulting in the suppression of Tcell proliferation and a reduction in the levels of LDHA (show LDHA Antibodies) and GLS2 (show GLS2 Antibodies)
ISG15 (show ISG15 Antibodies) is elevated in viremic HIV-1 patients and is associated with high TRAIL and IDO levels.
This insight into IDO1's involvement in pro-tumorigenic inflammatory neovascularization may have important ramifications for IDO1 inhibitor development, not only in cancer where clinical trials are currently ongoing, but in other disease indications associated with neovascularization as well.
Inhibition of IDO activity ameliorated Japanese encephalitis via enhancement of antiviral IFN-I/II innate and adaptive T-cell responses and increased central nervous system infiltration of peripheral leukocytes.
Data show that the expression of indoleamine 2, 3-dioxygenase 1 (IDO) was decreased after tumor cells were infected with Salmonella.
Severity of sodium dodecyl sulfate-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88 (show MYD88 Antibodies)-NF-kB transcriptional networks.
IDO1 deficiency does not affect inflammation in Systemic Juvenile Idiopathic Arthritis, Secondary Hemophagocytic Lymphohistiocytosis and a T cell-triggered cytokine release model.
Data indicate that indolamine-2,3-dioxygenase (IDO) and Fibroblast activation protein alpha (show FAP Antibodies) (FAPalpha) were detectable in B16 melanoma tumor-bearing mice.
Increased expression of IDO in liver cell adenomas compared to the surrounding normal tissue may create a microenvironment that promotes the progression of HCC (show FAM126A Antibodies) by suppressing the proliferation of cytotoxic T lymphocytes and enhancing Tregs.
Chimeric vaccine stimulation of human dendritic cell IDO1 occurs via the non-canonical NF-kappaB (show NFKB1 Antibodies) pathway.
Absence of Ido1 protects against atherosclerosis through increase of Il10 (show IL10 Antibodies).
This gene encodes indoleamine 2,3-dioxygenase (IDO) - a heme enzyme that catalyzes the first and rate-limiting step in tryptophan catabolism to N-formyl-kynurenine. This enzyme acts on multiple tryptophan substrates including D-tryptophan, L-tryptophan, 5-hydroxy-tryptophan, tryptamine, and serotonin. This enzyme is thought to play a role in a variety of pathophysiological processes such as antimicrobial and antitumor defense, neuropathology, immunoregulation, and antioxidant activity. Through its expression in dendritic cells, monocytes, and macrophages this enzyme modulates T-cell behavior by its peri-cellular catabolization of the essential amino acid tryptophan.
indoleamine-pyrrole 2,3 dioxygenase
, indoleamine 2,3-dioxygenase 2
, putative indoleamine 2,3-dioxygenase
, indoleamine 2,3-dioxygenase 1
, indolamine 2,3 dioxygenase
, indole 2,3-dioxygenase
, indoleamine-pyrrole 2,3-dioxygenase
, indoleamine 23-dioxygenase